Related Experiment Video
Updated: May 17, 2026
06:58
A Behavioral Screen for Heat-Induced Seizures in Mouse Models of Epilepsy
Published on: July 12, 2021
SCN1A IVS5N+5 polymorphism and response to sodium valproate: a multicenter study
Batoul Sadat Haerian1, Larry Baum, Hui Jan Tan
1Pharmacogenomics Laboratory, Department of Pharmacology, University of Malaya, Kuala Lumpur, Malaysia. batoolsadat@yahoo.com
Pharmacogenomics
|October 13, 2012
Summary
This study investigated the SCN1A IVS5N+5 polymorphism
Area of Science:
- Pharmacogenomics
- Epilepsy Research
- Genetic Polymorphisms
Background:
- Approximately 30% of epilepsy patients exhibit resistance to antiepileptic drugs (AEDs).
- The SCN1A IVS5N+5 polymorphism is a potential factor influencing AED response.
- Understanding genetic predictors of treatment response is crucial for personalized epilepsy management.
Purpose of the Study:
- To investigate the association between the SCN1A IVS5N+5 polymorphism and response to sodium valproate (VPA) monotherapy in Malaysian and Hong Kong Chinese epilepsy patients.
- To conduct a meta-analysis of existing studies to confirm or refute this association.
Main Methods:
- Genotyping of the SCN1A IVS5N+5 polymorphism in 583 epilepsy patients (Malaysian and Hong Kong Chinese) on VPA monotherapy.
- Meta-analysis of the current study with related association studies using fixed- and random-effects models.
Main Results:
- A total of 47.5% of patients were VPA nonresponsive and 52.5% were responsive.
- No significant association was found between the SCN1A IVS5N+5 polymorphism and VPA response in the overall cohort.
- A potential association was observed in Malay patients with idiopathic generalized epilepsy, likely due to small sample size.
Conclusions:
- The cohort study and meta-analysis did not establish a link between the SCN1A IVS5N+5 polymorphism and antiepileptic drug responsiveness.
- Larger-scale studies focusing on Malay individuals with idiopathic generalized epilepsy are recommended for further investigation.
Related Concept Videos
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...